- Home
- GOSS vs FLNA Comparison
GOSS vs FLNA Comparison
Compare GOSS & FLNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GOSS | FLNA |
|---|---|---|
| Founded | 2015 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.8M | 61.8M |
| IPO Year | 2018 | 2000 |
Fundamental Metrics
Financial Performance| Metric | GOSS | FLNA |
|---|---|---|
| Price | $8.54 | $0.69 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $95.40 | $6.50 |
| AVG Volume (30 Days) | 279.9K | ★ 4.7M |
| Earning Date | 11-04-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $48,471,000.00 | $41,119,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.11 | $0.67 |
| 52 Week High | $12.52 | $2.03 |
Technical Indicators
Market Signals| Indicator | GOSS | FLNA |
|---|---|---|
| Relative Strength Index (RSI) | 49.24 | 37.69 |
| Support Level | $0.18 | N/A |
| Resistance Level | $12.49 | $1.03 |
| Average True Range (ATR) | 0.76 | 0.06 |
| MACD | -0.59 | -0.02 |
| Stochastic Oscillator | 7.22 | 2.26 |
Price Performance
Historical ComparisonAbout GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).
About FLNA Filana Therapeutics Inc. Common Stock
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.